$SUJA

SUJA LIFE, INC. (SUJA): Entry into a Material Definitive Agreement

SUJA LIFE, INC. (SUJA) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 2 suja-arcreditagreement20.htm EX-10.1 suja-arcreditagreement20 AMENDED AND RESTATED CREDIT AGREEMENT Dated as of August 20, 2026 by and among SUJA LIFE INTERMEDIATE II, LLC, as Holdings, SUJA LIFE, LLC, as Borrower, THE LENDERS AND THE ISSUING LENDER PARTY HERETO, and JP

Original reporting
Published Aug 20, 2026, 8:16 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 20, 2026, 8:18 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefCorporate actions
Primary signal
$SUJA
Bullish
medium confidence
Mentioned
$SUJA
Relevance
6/10
alphai data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$SUJABullishMed
01

Why it matters

The financing arrangement may enhance the company's balance sheet and support operational growth.

02

Market read

The filing provides new financing details for SUJA, which could affect its stock valuation.

03

What to watch

Terms of the agreement, such as interest rates and covenants, are not disclosed.

Relevance 6/10Novelty 7/10Timing: filed Aug 20 2026

Background

SUJA Life, a maker of plant‑based beverages, disclosed a material definitive agreement via an SEC Form 8‑K.

Company-level read

Ticker impact

$SUJABullishMedium confidence
Context

SUJA Life filed an 8‑K reporting an amended and restated credit agreement with JPMorgan Chase, PNC Capital Markets and U.S. Bank as arrangers.

Expected impact

Potential modest upside as financing risk decreases.

Evidence & confidence

Access to additional credit reduces refinancing risk and can fund expansion, which is generally viewed favorably by investors.

Market effects

May signal increased financing activity in the health‑and‑wellness sector.

Limited to U.S. markets where SUJA is listed.

Minimal global impact beyond niche investors.

Counterpoint

The credit line could be used to cover cash burn, indicating underlying financial strain.

Key entities

  • JPMorgan Chase Bank, N.A.

    Administrative agent and lead arranger for the credit facility.

  • PNC Capital Markets, LLC

    Joint lead arranger for the credit facility.

  • U.S. Bank, National Association

    Joint lead arranger for the credit facility.

Related articles

$SUJAMed

Suja Defies Grocery Slowdown With Double-Digit Sales Growth in Q2

Suja Life, Inc. (Nasdaq: SUJA) reported Q2 net sales up 11.6% year over year to $83.9 million, citing volume growth and improved distribution. Gross profit increased 9.9% to $39.2 million, or 46.7% of sales. The company raised its 2026 outlook to $360 to $369 million net sales from $326.6 million in 2025.

$SUJAMed

SUJA LIFE, INC. (SUJA): Results of Operations and Financial Condition

SUJA LIFE, INC. (SUJA) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 sujalifeq22026earningsrele.htm EX-99.1 Document Suja Life Reports Second Quarter 2026 Financial Results Net sales increased 11.6% year-over-year to $83.9 million Updates fiscal year 2026 outlook OCEANSIDE, CA, August 4, 2026 – Suja Life, Inc. (NASDAQ: SUJA) (“Suja Life,

$SUJAMedAI 9/10

Suja Life Reports First Quarter 2026 Financial Results

Suja Life (NASDAQ: SUJA) reported first-quarter 2026 net sales of $107.1 million, up 22.5% year over year from $87.4 million. Adjusted EBITDA rose 66.3% to $25.0 million, with margin expanding to 23.4%. Net income was $7.7 million versus a prior-year net loss. The company initiated 2026 guidance: net sales $367–$371 million and Adjusted EBITDA $70–$72 million.

$SUJAMed

Suja Life (NASDAQ:SUJA) Upgraded to “Strong-Buy” at Evercore

Evercore upgraded Suja Life (NASDAQ:SUJA) to a “strong-buy” rating in a Monday research note, according to Zacks.com. Other firms also initiated coverage: Goldman Sachs set a $31 target and a “buy,” Jefferies set a $25 target and a “buy,” and William Blair rated “outperform.” MarketBeat data show a consensus “Buy” and average target $26.67.

$NVDAMed

Here are Monday's biggest analyst calls: Nvidia, Apple, Tesla, Broadcom, Microsoft, IBM, Meta, Tyson Foods & more

Wall Street analysts issued multiple calls Monday. Goldman initiated HawkEye 360 as buy; Morgan Stanley upgraded Dell to equal weight; Wells Fargo upgraded Tandem Diabetes Care to overweight. Citizens initiated Microsoft at Market Outperform with a $550 target; Barclays initiated IBM at overweight with a $350 target. Cantor reiterated Tesla overweight; RBC reiterated Meta outperform. Broadcom was reiterated overweight by Morgan Stanley, raising its target to $485.

$CBTMedAI 8/10

Cabot’s New US$350 Million Bond Issue Might Change The Case For Investing In CBT

Cabot Corporation issued US$350 million in senior unsecured notes due 2029, altering its funding mix. The move may impact investor views on balance sheet flexibility, especially as earnings have softened. Q3 2026 results showed US$6 million net income on US$982 million sales, with full-year EPS guidance of US$2.77. The company projects US$4.0 billion revenue and US$479.7 million earnings by 2029.